How to buy Antisense Therapeutics shares | A$0.115
Own Antisense Therapeutics shares in just a few minutes.
Antisense Therapeutics Limited is a drug manufacturers—specialty & generic business based in Australia. Antisense Therapeutics shares (ANP) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.115 – the same closing value as a week prior. Antisense Therapeutics has a trailing 12-month revenue of around $668,433.
How to buy shares in Antisense Therapeutics
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Antisense Therapeutics. Find the share by name or ticker symbol: ANP. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Antisense Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $0.115, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Antisense Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Antisense Therapeutics key stats
- Compare share trading platforms
- Is Antisense Therapeutics stock a buy or sell?
- Antisense Therapeutics performance over time
- Antisense Therapeutics's financials
- How volatile are Antisense Therapeutics shares?
- Does Antisense Therapeutics pay a dividend?
- Have Antisense Therapeutics shares ever split?
- Other common questions
How has coronavirus impacted Antisense Therapeutics's share price?
Since the stock market crash in March caused by coronavirus, Antisense Therapeutics's share price has had significant positive movement.
Its last market close was $0.115, which is 34.78% up on its pre-crash value of $0.075 and 296.55% up on the lowest point reached during the March crash when the shares fell as low as $0.029.
If you had bought $1,000 worth of Antisense Therapeutics shares at the start of February 2020, those shares would have been worth $468.75 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,796.88.
Antisense Therapeutics share priceUse our graph to track the performance of ANP stocks over time.
Antisense Therapeutics shares at a glance
|Latest market close||AUDA$0.115|
|52-week range||AUDA$0.029 - AUDA$0.13|
|50-day moving average||AUDA$0.0905|
|200-day moving average||AUDA$0.0699|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||AUDA$-0.008|
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Antisense Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Antisense Therapeutics price performance over time
|1 week (2020-09-23)||0%|
|1 month (2020-08-28)||26.37%|
|3 months (2020-06-30)||55.41%|
|6 months (2020-03-30)||144.68%|
|1 year (2019-09-30)||47.44%|
|2 years (2018-09-28)||538.89%|
|3 years (2017-09-29)||216.80%|
|5 years (2015-09-30)||36.42%|
Antisense Therapeutics financials
|Gross profit TTM||$464,631|
|Return on assets TTM||-82.84%|
|Return on equity TTM||-160.97%|
|Market capitalisation||$56.2 million|
TTM: trailing 12 months
Antisense Therapeutics share dividends
We're not expecting Antisense Therapeutics to pay a dividend over the next 12 months.
Have Antisense Therapeutics's shares ever split?
Antisense Therapeutics's shares were split on a 1:10 basis on 5 November 2013. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Antisense Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Antisense Therapeutics shares which in turn could have impacted Antisense Therapeutics's share price.
Antisense Therapeutics share price volatility
Over the last 12 months, Antisense Therapeutics's shares have ranged in value from as little as $0.029 up to $0.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Antisense Therapeutics's is 1.1747. This would suggest that Antisense Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Antisense Therapeutics overview
Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.
Frequently asked questions
Ask an Expert